Sukumar Nagendran Sells 26,918 Shares of Taysha Gene Therapies (NASDAQ:TSHA) Stock

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) insider Sukumar Nagendran sold 26,918 shares of Taysha Gene Therapies stock in a transaction dated Monday, January 26th. The stock was sold at an average price of $4.61, for a total transaction of $124,091.98. Following the transaction, the insider owned 1,317,389 shares of the company’s stock, valued at approximately $6,073,163.29. The trade was a 2.00% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.

Sukumar Nagendran also recently made the following trade(s):

• On Friday, January 23rd, Sukumar Nagendran sold 89,132 shares of Taysha Gene Therapies stock. The shares were sold at an average price of $4.75, for a total value of $423,377.00.
• On Monday, January 12th, Sukumar Nagendran sold 200,000 shares of Taysha Gene Therapies stock. The shares were sold at an average price of $4.71, for a total transaction of $942,000.00.
• On Friday, November 28th, Sukumar Nagendran sold 110,125 shares of Taysha Gene Therapies stock. The shares were sold at an average price of $4.75, for a total transaction of $523,093.75.
• On Monday, December 1st, Sukumar Nagendran sold 260,047 shares of Taysha Gene Therapies stock. The stock was sold at an average price of $4.51, for a total value of $1,172,811.97.

Taysha Gene Therapies Stock Performance

Taysha Gene Therapies stock opened at $4.48 on Thursday. The stock has a fifty day moving average price of $5.10 and a 200 day moving average price of $4.09. Taysha Gene Therapies, Inc. has a 52 week low of $1.05 and a 52 week high of $6.02. The firm has a market capitalization of $1.23 billion, a P/E ratio of -13.58 and a beta of 1.02. The company has a current ratio of 10.48, a quick ratio of 10.48 and a debt-to-equity ratio of 0.23.

Taysha Gene Therapies (NASDAQ:TSHA) last issued its quarterly earnings results on Tuesday, November 4th. The company reported ($0.09) EPS for the quarter, hitting the consensus estimate of ($0.09). Taysha Gene Therapies had a negative net margin of 1,144.97% and a negative return on equity of 67.26%. Equities research analysts anticipate that Taysha Gene Therapies, Inc. will post -0.35 earnings per share for the current year.

Institutional Investors Weigh In On Taysha Gene Therapies

Institutional investors and hedge funds have recently made changes to their positions in the company. Marex Group plc acquired a new position in Taysha Gene Therapies in the second quarter worth $29,000. E Fund Management Co. Ltd. acquired a new stake in shares of Taysha Gene Therapies during the second quarter worth $31,000. ST Germain D J Co. Inc. lifted its position in shares of Taysha Gene Therapies by 81.8% in the 3rd quarter. ST Germain D J Co. Inc. now owns 9,633 shares of the company’s stock worth $32,000 after buying an additional 4,333 shares during the last quarter. May Hill Capital LLC bought a new position in shares of Taysha Gene Therapies in the 2nd quarter worth about $37,000. Finally, Arrowpoint Investment Partners Singapore Pte. Ltd. acquired a new position in shares of Taysha Gene Therapies in the 3rd quarter valued at about $40,000. 77.70% of the stock is owned by institutional investors and hedge funds.

More Taysha Gene Therapies News

Here are the key news stories impacting Taysha Gene Therapies this week:

• Positive Sentiment: Analyst outlook remains constructive: several firms have raised price targets and reiterated buy/outperform ratings (Wells Fargo, Robert W. Baird, Needham, JMP, Citizens/JMP). This supports upside vs. current levels.
• Positive Sentiment: Notable institutional activity: multiple funds reported adding or building positions (MarketBeat summary highlights large additions), which can be a longer‑term vote of confidence.
• Neutral Sentiment: Recent earnings matched estimates (Q3 EPS -$0.09), and consensus expects continued losses this year — typical for a clinical‑stage biotech; no near‑term revenue catalysts were reported. Earnings & Consensus
• Neutral Sentiment: Technical/market context: shares had elevated volume vs. average and sit between the 50‑day (~$5.09) and 200‑day (~$4.08) moving averages; valuation remains typical for pre‑revenue gene therapy names (negative P/E). Quote & Technicals
• Negative Sentiment: Insider selling — CFO Kamran Alam: sold 78,968 shares (Jan. 23) and 23,849 shares (Jan. 26), reducing his stake; the Jan. 26 sale filed with the SEC. CFO Form 4
• Negative Sentiment: Insider selling — CEO Sean P. Nolan: sold 136,789 shares (Jan. 23) and 41,312 shares (Jan. 26), reducing his ownership; filings are public with the SEC. CEO Form 4
• Negative Sentiment: Insider selling — director Sukumar Nagendran: sold 89,132 shares (Jan. 23) and 26,918 shares (Jan. 26), further insider reductions reported. Director Form 4

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on the company. Chardan Capital reiterated a “buy” rating and issued a $12.00 target price on shares of Taysha Gene Therapies in a research note on Tuesday, January 6th. Citizens Jmp increased their price objective on shares of Taysha Gene Therapies from $6.00 to $8.00 and gave the company a “market outperform” rating in a research report on Wednesday, November 5th. Wells Fargo & Company boosted their target price on shares of Taysha Gene Therapies from $8.00 to $11.00 and gave the stock an “overweight” rating in a research report on Monday, January 5th. Citigroup restated an “outperform” rating on shares of Taysha Gene Therapies in a research note on Wednesday, November 5th. Finally, JMP Securities set a $8.00 price target on shares of Taysha Gene Therapies in a research note on Wednesday, November 5th. One analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Taysha Gene Therapies presently has a consensus rating of “Moderate Buy” and an average price target of $10.67.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc (NASDAQ: TSHA) is a clinical-stage biotechnology company focused on developing gene therapies for rare monogenic diseases of the central nervous system. Using a proprietary adeno-associated viral (AAV) vector platform, the company engineers novel capsids and regulatory elements to optimize delivery and expression of therapeutic genes. Its pipeline features lead programs such as TSHA-102 for GM2 gangliosidoses (Tay–Sachs and Sandhoff diseases), TSHA-101 for GM1 gangliosidosis and TSHA-103 for aromatic l-amino acid decarboxylase (AADC) deficiency, alongside earlier-stage candidates targeting other life-threatening pediatric CNS disorders.

Founded in 2019 and headquartered in Dallas, Texas, Taysha Gene Therapies completed its initial public offering in May 2021.